about
Intestinal Immunity and Gut Microbiota as Therapeutic Targets for Preventing Atherosclerotic Cardiovascular DiseasesExpression of G2A, a receptor for lysophosphatidylcholine, by macrophages in murine, rabbit, and human atherosclerotic plaquesCentral role of calcium-dependent tyrosine kinase PYK2 in endothelial nitric oxide synthase-mediated angiogenic response and vascular functionCD3 antibody and IL-2 complex combination therapy inhibits atherosclerosis by augmenting a regulatory immune response.Endothelial NO synthase overexpression inhibits lesion formation in mouse model of vascular remodeling.Maternal immunization affects in utero programming of insulin resistance and type 2 diabetes.Analysis of Gut Microbiota in Coronary Artery Disease Patients: a Possible Link between Gut Microbiota and Coronary Artery Disease.Characterization of gut microbiota profiles in coronary artery disease patients using data mining analysis of terminal restriction fragment length polymorphism: gut microbiota could be a diagnostic marker of coronary artery disease.Gut Microbiota and Coronary Artery Disease.Intestinal Immunity and Gut Microbiota in Atherogenesis.Regulatory T cells in atherogenesis.Dendritic cells in atherogenesis: possible novel targets for prevention of atherosclerosis.Regulatory T cells and tolerogenic dendritic cells as critical immune modulators in atherogenesis.Anti-inflammatory and immune-modulatory therapies for preventing atherosclerotic cardiovascular disease.Ultraviolet B Exposure Inhibits Angiotensin II-Induced Abdominal Aortic Aneurysm Formation in Mice by Expanding CD4+Foxp3+ Regulatory T Cells.In vivo angiographic detection of vascular lesions in apolipoprotein E-knockout mice using a synchrotron radiation microangiography system.Beneficial effect of anti-platelet therapies on atherosclerotic lesion formation assessed by phase-contrast X-ray CT imaging.Xenogenic macrophage immunization reduces atherosclerosis in apolipoprotein E knockout mice.Isolated primary cardiac sarcoidosis presenting as acute heart failure.Propagermanium reduces atherosclerosis in apolipoprotein E knockout mice via inhibition of macrophage infiltration.Impact of CD14++CD16+ monocytes on plaque vulnerability in diabetic and non-diabetic patients with asymptomatic coronary artery disease: a cross-sectional study.Foxp3+ regulatory T cells play a protective role in angiotensin II-induced aortic aneurysm formation in mice.Resistance to endotoxin shock in transgenic mice overexpressing endothelial nitric oxide synthase.A calcium channel blocker, benidipine, inhibits intimal thickening in the carotid artery of mice by increasing nitric oxide production.Oral administration of an active form of vitamin D3 (calcitriol) decreases atherosclerosis in mice by inducing regulatory T cells and immature dendritic cells with tolerogenic functions.Commensal bacteria at the crossroad between cholesterol homeostasis and chronic inflammation in atherosclerosis.Requirement of activation of the extracellular signal-regulated kinase cascade in myocardial cell hypertrophy.HMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats.Intramuscular gene transfer of interleukin-10 cDNA reduces atherosclerosis in apolipoprotein E-knockout mice.Maternal immunization programs postnatal immune responses and reduces atherosclerosis in offspring.Beneficial effects of exogenous tetrahydrobiopterin on left ventricular remodeling after myocardial infarction in rats: the possible role of oxidative stress caused by uncoupled endothelial nitric oxide synthase.Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.Atherosclerotic plaque imaging using phase-contrast X-ray computed tomography.UVB Exposure Prevents Atherosclerosis by Regulating Immunoinflammatory Responses.Impact of CD14++CD16+ monocytes on coronary plaque vulnerability assessed by optical coherence tomography in coronary artery disease patients.Regulatory/effector T-cell ratio is reduced in coronary artery disease.Regression of atherosclerosis with anti-CD3 antibody via augmenting a regulatory T-cell response in mice.Oral administration of the lactic acid bacterium Pediococcus acidilactici attenuates atherosclerosis in mice by inducing tolerogenic dendritic cells.Association between the rotation and three-dimensional tortuosity of the proximal ascending aorta.Oral anti-CD3 antibody treatment induces regulatory T cells and inhibits the development of atherosclerosis in mice.
P50
Q26799473-E3DB9C97-7E4E-487D-8920-C25BE9523973Q28217576-6035414B-7FD4-4015-B947-5B2E3068D795Q28594535-C79FC841-E581-41FE-B3FF-ABA5A10AD57CQ30426856-CBFF8BC9-13C5-47F4-81F4-26DB7419A722Q31825689-D2D98C49-4045-4633-8050-65D9C4EB1C3AQ34428867-3273AAC8-DDBC-4401-8C89-E88F745EE780Q35947075-B5A094FD-15CD-4481-BCE4-6D988BBAFF5BQ36002203-2F482763-6594-49B7-9347-178637165939Q36183854-477B7B6F-856F-42F3-987E-174A3FF4EA48Q36215494-70D9CC9B-7DBA-4132-BDD2-5AFB07772D47Q38002291-51CCC167-9407-463C-A6CB-E4ED133EB011Q38033447-2C6EB99D-FACC-47E7-938D-640411180173Q38259947-9AC21929-E5AD-4BC8-B06D-85C71D23EA13Q38368422-16624603-D4E6-4971-AD67-62C4E5C18A53Q38599154-04CDB881-EFB9-40A2-9735-876E9566ADAEQ39635269-0177170A-F046-4BE7-92F4-A909383DF928Q39737585-AC9F90E7-0E85-412E-96AC-189FA74F6120Q40122954-4E76CDA8-8344-4B4B-8A19-54EEDE1ADDF5Q40262014-5DC8E0D5-BFE8-40D6-90C6-2CB3FB678FCCQ40724596-0003379E-4D2D-41F0-9F43-67892BEE3E20Q41318423-D059CFE9-9757-4AEC-988B-13DC2671656BQ41533594-39659580-BC56-4B59-90E4-8A36263F533AQ42484284-52A9489C-B2C6-45A9-9DA3-6396A9A332B7Q42502447-57FF14D7-B63F-4C0B-AEE2-5EAB3FF1D1A4Q42866991-BB278FAC-A27D-41B5-A666-574E94D74E13Q43156960-5F6DA5E8-0795-4A21-8747-BC32314F930AQ43504863-9E18D30C-CF0A-4158-854B-7808E7268375Q44269132-A662D587-7C87-43FC-831A-5C3BF2D9B1BEQ44716925-1A6D771E-9A6A-4327-8ACD-EED53D8A623BQ46129921-C01631E4-F79D-490E-BF24-4E35237DEC2AQ46413466-2A15D755-6C4A-4438-9C30-BFC9D9590000Q46698760-B84D71F6-105E-4284-8B6B-2890C2F9382DQ46847348-E66AE942-7605-46A4-9E62-D5E63C1E329EQ48963849-274289B0-5455-4CEC-A955-0EFD8232195BQ50174733-2F96FCF2-E607-4DA3-AE4D-7EF6DE817D82Q51041466-69A839AA-4951-432A-8BF1-F396FD14B84BQ51760069-706E6E3F-2D27-42C0-8000-454C478EB243Q52792704-67B16442-4658-489D-B52C-F46C397955DEQ53057585-9A4BE5A5-932D-4439-A2B6-3F879B05D776Q53362260-F03CD4D2-C795-4666-A315-4A2CED997E03
P50
description
researcher
@en
name
T Yamashita
@en
T Yamashita
@nl
type
label
T Yamashita
@en
T Yamashita
@nl
prefLabel
T Yamashita
@en
T Yamashita
@nl
P106
P31
P496
0000-0003-0267-3842